Prix Galien 2014,U.K.: the winners

London, October 1st , 2014

Bexero® (Novartis) and Sirturo® (bedaquiline, Janssen) were the winners of Prix Galien 2014 in U.K.

The UK Prix Galien award ceremony took place at the House of Commons under the presidency of Rt Hon. Kevin BARRON MP.

The Innovative Product Award was won by Novartis’ Bexsero – the first broad coverage vaccine to help protect against meningitis B. Approved in the EU in 2013, Bexsero is indicated to help protect all age groups against meningococcal serogroup B disease, including infants – who are the most vulnerable. “Bexsero was the unanimous winner of the Innovative Product Award,” said Professor Sir Michael. “Invasive meningococcal disease manifests as either meningitis and/or septicaemia – which can be difficult to diagnose –and its rapid progression. Developing a vaccine, however, has been extremely difficult. It is thereforefantastic that the pioneering research at Novartis has led to the use of genomic techniques in creating abroadly protective vaccine.”

“Bexsero has already been recommended for inclusion in the UK’s immunisation schedule for infants – and we warmly applaud our new‐found ability to address what was a big gap in childhood disease prevention.”

Two further drugs were ‘highly commended’ by the judging panel; Dificlir® (Astellas) for Clostridium difficile infection, and Lemtrada® (Genzyme) for MS.

The 2014 Orphan Drug Award was won by Janssen’s bedaquiline Sirturo, the first medication for pulmonary multi-drug resistant tuberculosis (MDRTB) with a novel mechanism of action in over forty years. Sirturo (bedaquiline), which is administered by directly observed therapy, is indicated as part of combination therapy in adults with pulmonary MDRTB.

Three further orphan drugs were highly commended by the panel; Adempas® (Bayer) for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension, Esbriet® (InterMune) for idiopathic pulmonary fibrosis (IPF) and Kalydeco® (Vertex) for cystic fibrosis.

For additional information, please contact: Mrs. Jane GARMON JONES P. 44 (0)1494 470760,, Website :